Five things to know
- Must readRegeneron’s baloncibart, an NPR1-blocking antibody, slowed the heart rate rise on standing in a POTS Phase 2 One 450 mg dose cut it by 11.4 beats per minute vs placebo at day 8 in 82 adults, per Regeneron. The p-values are nominal and the effect shrank by day 29.Partial Partial NCT06593600 registers the change at day 8 and, for Cohort B only, the change in its average at day 29 as primaries; the release reports day 29 as a secondary; completed; 82 enrolled; primary c#
- Must readRezolute reports 13 of 16 responders in its Phase 3 of ersodetug in tumor hyperinsulinism Twelve of them stopped IV glucose, per the company. The data are preliminary, from a single-arm, open-label trial, with the full topline due by mid-December.Partial Partial NCT06881992 registers the share with a meaningful cut in IV glucose infusion at 8 weeks as the primary, 16 planned, recruiting, primary completion 09.2027; the release is a preliminary count b#
- Must readWindward Bio priced a $175M IPO at the midpoint with $50M from Sanofi; Vir raised $150M Both priced on a day XBI fell 3.3% and the 10-year Treasury yield rose to 5.10%. Rezera didn’t price as expected.#
- Know itArrowhead reports CSF tau down as much as 73% on average with ARO-MAPT, an siRNA against tau These are interim data in healthy volunteers; lower tau hasn’t yet been shown to slow disease.Partial Partial NCT07221344 registers adverse events through the end of the trial as the primary, not tau lowering; enrollment was raised to 160 from 112 on the registry; primary completion 06.2027. See 05B.#
- Know itVor Bio licensed a second BAFF and APRIL blocker from RemeGen for about $56M upfront RC298 is in IND-enabling work and has no human data yet; most of the upfront is paid in stock.#
Bright spot
Aravax reports that 39.4% of children on the top dose of its peptide therapy tolerated a cumulative dose of at least 443 mg of peanut protein vs 16.7% on placebo, with no treatment-related anaphylaxis, per the company. Full data are due at ACAAI on 11.14.
Verified today #
Claim Check #
| Readout | Registry says | Headline says | Verdict |
|---|---|---|---|
| Baloncibart · Regeneron PINNACLE · NCT06593600 | Phase 2. Primaries: change in heart rate from lying to standing at day 8; change in its average at day 29, Cohort B only. N=82. Completed; primary completion 05.06.2026. | −11.4 bpm vs placebo at day 8 (450 mg); −7.4 at day 29, reported as a secondary; the registered day 29 primary (average, Cohort B only) not reported; nominal p-values | Partial |
| Ersodetug · Rezolute upLIFT · NCT06881992 | Phase 3. Primary: share with a clinically meaningful cut in IV glucose infusion at 8 weeks. N=16 planned. Recruiting; primary completion 09.2027. | 13 of 16 responders (at least a 50% cut); preliminary, 3 still in the pivotal period | Partial |
| PVX108 · Aravax Phase 2 · NCT05621317 | Phase 2. Primary: ratio of maximum tolerated peanut dose at the week 46 food challenge vs baseline, ages 4 to 11. N=95 enrolled, ages 4 to 17; the result covers 71 aged 4 to 11. Active, not recruiting; primary completion 09.26.2025. | 2.4x vs 1.2x geometric mean fold change at month 12 (50 nmol) | Partial |
| ARO-MAPT · Arrowhead Phase 1/2a · NCT07221344 | Phase 1/2a. Primary: adverse events through end of trial, up to day 375. N=160 planned (was 112). Recruiting; primary completion 06.2027. | CSF total tau down up to 73% on average at day 105; interim | Partial |
Calendar #
| Date | Event | Who | Confirmed at |
|---|---|---|---|
| 2026-11-13 | October PPI, 8:30 am ET | BLS | BLS |
| 2026-11-14 | Goal date, IGALMI (sublingual dexmedetomidine) for agitation at home, set before the sale to Teva | BioXcel; Teva | Company |
| 2026-11-14 | Goal date, ivonescimab with chemotherapy in EGFR-mutant non-squamous lung cancer after a third-generation EGFR TKI; Summit’s Q3 8-K (11.04) says FDA noted that a statistically significant survival benefit is necessary in this setting | Summit | Company |
| 2026-11-14 | Goal date, aficamten (Myqorzo) label expansion in obstructive HCM; not yet confirmed at the company | Cytokinetics | Aggregator |
| 2026-11-14 | ObesityWeek, National Harbor; embargo lifts 11.14 at noon ET | Organizer | Press |
| 2026-11-16 | POLARIS-AD Phase 3 topline of oral AR1001 in Alzheimer’s disease, at CTAD, 4:05 pm ET | AriBio | Company |
| 2026-11-16 | Tender offer for Pacira at $36.50 a share in cash expires one minute after 11:59 pm ET, unless extended | Viatris; Pacira | Company |
| 2026-11-17 | Goal date, adrabetadex (NDA); not yet confirmed at the company | Beren | Aggregator |
| 2026-11-18 | Senate vote on Heidi Overton’s nomination as FDA commissioner, as reported; not confirmed on a Senate page | U.S. Senate | Press |
| 2026-11-22 | Goal date, molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis, after a review extension | Savara | Company |
| 2026-11-22 | Goal date, deramiocel cell therapy in Duchenne muscular dystrophy, extended from 08.22 after a major amendment that asked FDA to consider a refined indication focused on upper limb function, per Capricor (08.24); follows a 9 to 3 advisory committee vote against approval (07.29), as reported by trade press | Capricor | Company |
| 2026-11-25 | Goal date, venglustat in type 3 Gaucher disease (priority review) | Sanofi | Company |
| 2026-11-27 | Goal date, BBP-418 in limb-girdle muscular dystrophy 2I/R9 (priority review); restated in BridgeBio’s Q3 release (10.29), which says no advisory committee is planned | BridgeBio | Company |
| 2026-11-27 | Goal date, neladalkib in TKI-pretreated ALK-positive lung cancer, per Nuvalent (05.27) | Nuvalent | Company |
| 2026-11-27 | Goal date, saroglitazar (NDA); not yet confirmed at the company | Zydus | Aggregator |
| 2026-11-28 | Goal date, D-PLEX100 to prevent surgical site infection in abdominal colorectal surgery (priority review) | PolyPid | Company |
| 2026-11-30 | Goal date, bezuclastinib with sunitinib in GIST after imatinib (priority review) | Cogent | Company |
| 2026-11-30 | Goal date, povetacicept in IgA nephropathy (accelerated approval), per Vertex (06.01) | Vertex | Company |
| 2026-11-30 | Goal date, giredestrant in ER-positive early breast cancer (priority review) | Roche | Company |
| 2026-11-30 | CMS deadline to publish third-cycle negotiated prices, which take effect in 2028 | CMS | CMS |
| 2026-12-08 | FOMC meeting; statement 12.09, 2:00 pm ET | Federal Reserve | Fed |
| 2026-12-12 | ASH Annual Meeting, New Orleans | ASH | Organizer |
| 2026-12-12 | Goal date, imsidolimab in generalized pustular psoriasis | Vanda | Company |
| 2026-12-19 | Goal date, imlifidase for highly sensitized patients awaiting a kidney transplant | Hansa | Company |
| 2026-12-22 | Goal date, lorundrostat in hypertension, reconfirmed in Q3 results (11.04) | Mineralys | Company |
| 2026-12-23 | Goal date, anitocabtagene autoleucel in fourth-line or later multiple myeloma, per 8-K exhibit | Arcellx; Kite | Company |
| 2026-12-30 | Goal date, bezuclastinib in nonadvanced systemic mastocytosis, per Cogent (03.16) | Cogent | Company |
| 2027-01-21 | Goal date, z-rostudirsen in Duchenne (exon 51), per Q3 results (11.05) | Dyne | Company |
| 2027-02-01 | New goal date, mitapivat in sickle cell disease, after a major amendment (moved from 11.01) | Agios | Company |
| 2027-02-28 | Goal date, QTORIN rapamycin in microcystic lymphatic malformations (priority review), per Q3 report (11.05) | Palvella | Company |
| 2027-03-03 | Goal date, zanzalintinib with atezolizumab in colorectal cancer, after a review extension; trade press only | Exelixis | Press |
| 2027-03-10 | Goal date, lonvo-z in hereditary angioedema; FDA not currently planning an advisory committee, Intellia says (Q3 results, 11.05) | Intellia | Company |
| 2027-04-09 | Goal date, rivoceranib with camrelizumab in unresectable liver cancer, after a third complete response letter; trade press only | Elevar; Hengrui | Press |
| 2027-05-01 | Goal date, AMT-130 (ifezuntirgene inilparvovec) in Huntington’s disease, BLA under priority review, seeking accelerated approval; FDA is tentatively planning an advisory committee, uniQure says | uniQure | Company |
Registry Watch #
| Trial | Field | Was | Now |
|---|---|---|---|
| ALTITUDE-AD (Acumen sabirnetug) · NCT06335173 | Primary completion | 10.2026 | 10.29.2026 |
| ALTITUDE-AD (Acumen sabirnetug) · NCT06335173 | Completion | 10.2026 | 12.2026 |
| ARO-MAPT Ph1/2a · NCT07221344 | Enrollment | 112 | 160 |
| ARO-MAPT Ph1/2a · NCT07221344 | Primary outcome | TEAEs through Day 315 | TEAEs through end of trial, up to Day 375 |
| COURAGE (trevogrumab) Ph2 · NCT06299098 | Status | Active, not recruiting | Completed |
Download the full briefPDF, 27 pages
Track record: our calls, graded in public · corrections log
Want this by email? Join Mind Club. It's complimentary.